Preprint Article Version 2 Preserved in Portico This version is not peer-reviewed

Metformin Therapy and Breast Cancer Incidence in the Hail Region

Version 1 : Received: 11 December 2022 / Approved: 14 December 2022 / Online: 14 December 2022 (03:33:08 CET)
Version 2 : Received: 1 January 2023 / Approved: 13 January 2023 / Online: 13 January 2023 (07:29:32 CET)

A peer-reviewed article of this Preprint also exists.

Osman, M.; Muqbel, T.; Alenzi, A.; Alenzi, S.; Kalifa, N.E.; Khojali, W.M.; Elagib, H.M.; Hussein, W.; Abdallah, M.H. Metformin Therapy and Breast Cancer Incidence in the Ha’il Region. Healthcare 2023, 11, 321. Osman, M.; Muqbel, T.; Alenzi, A.; Alenzi, S.; Kalifa, N.E.; Khojali, W.M.; Elagib, H.M.; Hussein, W.; Abdallah, M.H. Metformin Therapy and Breast Cancer Incidence in the Ha’il Region. Healthcare 2023, 11, 321.

Abstract

Background: Metformin is a drug used to treat patients with type 2 diabetes, especially those who suffer from obesity. It is also used in the treatment of women with polycystic ovary syndrome (PCOS). This disease has been shown to be related to insulin resistance and multiplied blood sugar ranges. Further, it has been found that the use of metformin improves the menstrual cycles and ovulation rates of these women. Methods: A structured questionnaire will be conducted to determine the prevalence of breast cancer among women using metformin in the Ha’il region. Result: Incidence of breast cancer among women using metformin in the Ha’il region is very low. Conclusions: According to previous findings, metformin has been linked to lower breast cancer risk in women with type 2 diabetes. Furthermore, the findings of this study have corroborated the literature for the same by indicating that there is a substantial connection between metformin use and a lower risk of breast cancer in women with type 2 diabetes

Keywords

breast cancer; diabetes; metformin

Subject

Medicine and Pharmacology, Pharmacology and Toxicology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.